#USA #New York #Pomerantz LLP #Capricor Therapeutics #CAPR

Pomerantz Law Firm Probes Capricor Therapeutics

Pomerantz LLP, a renowned law firm with a rich legacy in corporate litigation, is currently investigating claims on behalf of the investors of Capricor Therapeutics, Inc., a company listed on NASDAQ under the ticker symbol CAPR. This investigation is vital for safeguarding investors' rights as concerns arise over possible securities fraud and unlawful business practices committed by Capricor's management and board.

Background of the Investigation

The law firm’s investigation surfaced following significant announcements from Capricor that affected its stock value sharply. On May 5, 2025, Capricor issued a press release regarding its Biologics License Application (BLA) for deramiocel, an innovative cell therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy. This announcement detailed a meeting with the U.S. Food and Drug Administration (FDA), which confirmed the scheduling of an advisory committee meeting to discuss the BLA further. Following this news, Capricor's stock suffered a considerable setback. The share price plummeted by $3.00, marking a 29.13% decline, closing at $7.30 on May 6, 2025.

Further turmoil ensued when, on June 20, 2025, STAT, a reputable publication, reported that the new head of the FDA's division overseeing the relevant review canceled the previously announced advisory committee meeting. The cancellation stemmed from burgeoning uncertainties surrounding the efficacy and safety data for deramiocel, which led to another significant decline in Capricor’s stock price—this time by $3.68 or 30.82%, closing at $8.26 per share.

Implications for Investors

These abrupt changes in stock performance have prompted concerns among investors regarding potential breaches of fiduciary duty by Capricor’s executives. Pomerantz LLP encourages impacted investors to reach out for assistance. Danielle Peyton, a representative from the firm, has been designated as the contact for any investors who may wish to join ongoing class action efforts to seek justice against any wrongdoing identified during their investigation.

Pomerantz's Track Record

Founded over 85 years ago by renowned attorney Abraham L. Pomerantz, the firm is widely recognized for its pioneering role in securities class actions. Pomerantz LLP has secured numerous multimillion-dollar awards for clients, establishing it as a leader in protecting investors' rights affected by corporate misconduct. Their commitment to fighting against breaches in fiduciary duty and securities fraud remains unwavering.

Investors are reminded that previous case results do not guarantee similar outcomes, but the firm’s extensive experience in this domain ensures that stakeholders have a strong ally in the fight for justice.

For further inquiries or if you are an investor needing assistance, please contact Danielle Peyton at [email protected] or by dialing 646-581-9980, ext. 7980.

Conclusion

The ongoing investigation by Pomerantz LLP into Capricor Therapeutics reflects the firm’s dedication to consumer protection and integrity in the financial markets. As these events develop, stakeholders are advised to stay informed and consider legal recourse if they were adversely affected by Capricor’s business practices.